Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investors for the private placement of 2,289,638 ordinary shares of the Company, at a price of The ordinary shares to be issued by Intec in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in , absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements.
Category: Securities and Exchange Commission
Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into a securities purchase agreement with certain of its existing investors for the sale of $8.0 million of the Company’s Series A Convertible Preferred Stock and accompanying common stock warrants . Fibrocell has agreed to sell an aggregate of 8,000 units for a purchase price of $1,000 per Unit, with each Unit consisting of one share of Preferred Stock with an initial stated value of $1,000 convertible into shares of the Company’s common stock at a conversion price of $0.7757, and Warrants to purchase 10,313,263 shares of Common Stock .
Medovex Corp. Completes Financing
On February 9, 2017, Medovex Corporation entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000.
NEWS DuPont, Chemours to pay $670 million to settle PFOA claims
… Exchange Commission that it reached a “settlement in principle” with plaintiffs to resolve 3,550 lawsuits that allege health problems ranging from cancer to high cholesterol and thyroid problems. The settlement comes on the heels of a decision last …
Virtus Investment Advisers Inc. Acquires New Position in Humana Inc.
… company’s stock. The company has a consensus rating of “Buy” and an average price target of $213.00. Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail …
Check Cap LTD (Chek) Coverage Initiated by Analysts at Rodman & Renshaw
The brokerage issued a buy rating and a $6.00 price target on the stock. Separately, Maxim Group set a $6.00 target price on shares of CHECK CAP LTD and gave the company a buy rating in a report on Monday, October 24th.
Press release distribution, EDGAR filing, XBRL, regulatory filings
… 5 – 8, 20… )–The U.S. Centers for Disease Control and Prevention (CDC) has selected ICF and its award-winning health communications practice for nine contracts with a combined val… )–Research and Markets has announced the addition of the “Fuel …
Exelixis Inc. (EXEL) Stake Raised by Swiss National Bank
Swiss National Bank increased its position in shares of Exelixis Inc. by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 367,300 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period.